Cargando...
Diffuse Alveolar Hemorrhage Secondary to Ibrutinib Therapy in a Patient With Refractory Mantle Cell Lymphoma
Ibrutinib is a Bruton tyrosine kinase inhibitor that is approved by the FDA for the treatment of mantle cell lymphoma and other hematological malignancies. Bruton tyrosine kinases promote platelet aggregation, and, therefore, bleeding is a common side effect of ibrutinib. At least half of patients t...
Guardado en:
| Publicado en: | Cureus |
|---|---|
| Autores principales: | , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Cureus
2020
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7377008/ https://ncbi.nlm.nih.gov/pubmed/32714681 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.8743 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|